Gendux AB
Högbergsgatan 32
Stockholm
SE-116 20
Tel: 46-8-556-091-89
Fax: 46-8-442-72-39
Website: http://www.gendux.com/
Email: info@gendux.com
About Gendux AB
AUSTIN, Texas and LONDON, Sept. 17 /PRNewswire/ -- Introgen Therapeutics, a world leader in the development of gene-based therapeutics to treat cancer, today announced the formation of Gendux Inc., a wholly owned subsidiary. Gendux will utilize the product development and manufacturing processes, research and development infrastructure, clinical and regulatory expertise, business development and licensing experience and proven gene delivery technologies of Introgen Therapeutics, to move its therapeutic candidates to product commercialization in a rapid timeframe.4 articles about Gendux AB
-
Gendux Announces Acceptance of Its ADVEXIN Marketing Authorization Application for Review by the European Medicines Evaluation Agency
11/27/2007
-
Introgen Therapeutics, Inc. and Gendux Submit First Marketing Authorization Application for ADVEXIN
11/13/2007
-
Introgen Therapeutics, Inc. And Gendux Announce Agreement With European Medicines Agency To File For ADVEXIN Approval Under Exceptional Circumstance Rules
10/31/2006
-
Introgen Therapeutics, Inc. And Gendux Announce Orphan Designation For ADVEXIN Therapy In European Union
9/7/2006